NCT03764826 is a NA clinical trial of CAABT in Tinnitus, sponsored by Beijing Friendship Hospital.

Who is sponsoring NCT03764826?

NCT03764826 is sponsored by Beijing Friendship Hospital.

What drugs are being tested in NCT03764826?

Interventions in NCT03764826: CAABT, TMT.

Is NCT03764826 still recruiting?

NCT03764826 is currently status unknown. Last updated 11 December 2018.

Last reviewed 2018-12-11 · How we verify

NCT03764826

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study on the Effect of Sound Therapy on Chronic Primary Tinnitus

Status unknown NA Last updated 11 December 2018

What this trial tests

NA trial testing CAABT in Tinnitus in 100 participants. Status unknown.

Timeline

1 December 2018

Primary endpoint
8 June 2019

8 December 2019

Quick facts

Lead sponsor	Beijing Friendship Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	100
Start date	1 December 2018
Primary completion	8 June 2019
Estimated completion	8 December 2019
Sites	1 location across China

Drugs / interventions tested

CAABT
TMT

Conditions studied

Tinnitus — all drugs for Tinnitus →

Sponsor

Beijing Friendship Hospital

Who can join

Adults 18 to 75, any sex, with Tinnitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study is to compare the effect of Cochleural Alternating Acoustic Beam Therapy(CAABT) and tinnitus masking therapy(TMT) on chronic primary tinnitus.Half of participants will receive CAABT, while the other half will receive TMT.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Distinct brain structural-functional network topological coupling explains different outcomes in tinnitus patients treated with sound therapy.
Chen Q, Lv H, Wang Z, Wei X, et al · · 2022 · cited 26× · PMID 35332961 · DOI 10.1002/hbm.25848
Outcomes at 6 months are related to brain structural and white matter microstructural reorganization in idiopathic tinnitus patients treated with sound therapy.
Chen Q, Lv H, Wang Z, Wei X, et al · · 2021 · cited 23× · PMID 33098363 · DOI 10.1002/hbm.25260
Pretreatment intranetwork connectivity can predict the outcomes in idiopathic tinnitus patients treated with sound therapy.
Chen Q, Lv H, Wang Z, Wei X, et al · · 2021 · cited 12× · PMID 34231944 · DOI 10.1002/hbm.25584
Brain Structural and Functional Reorganization in Tinnitus Patients Without Hearing Loss After Sound Therapy: A Preliminary Longitudinal Study.
Chen Q, Lv H, Wang Z, Wei X, et al · · 2021 · cited 10× · PMID 33776630 · DOI 10.3389/fnins.2021.573858
Multimodal quantitative magnetic resonance imaging of the thalamus in tinnitus patients with different outcomes after sound therapy.
Chen Q, Lv H, Wang Z, Li X, et al · · 2023 · cited 5× · PMID 37392024 · DOI 10.1111/cns.14330

Verify or expand the search:

Other recruiting trials for Tinnitus

Currently open trials in the same condition.

NCT07393880 — Bimodal Electrical-Sound Stimulation and Auditory Training for Chronic Tonal Tinnitus · NA · recruiting
NCT07071480 — Noninvasive Therapy for Tinnitus · NA · recruiting
NCT07435298 — Navigated Repetitive TMS for Chronic Tinnitus · NA · recruiting
NCT07158034 — Investigating EEG as a Biomarker for Tinnitus Improvement After Bimodal Stimulation · NA · recruiting
NCT07017998 — External Therapy for Tinnitus Management · NA · recruiting

Other Beijing Friendship Hospital trials

Trials by the same sponsor.

NCT07453862 — Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety · Phase 1 · recruiting
NCT07397442 — Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer · Phase 2 · not yet recruiting
NCT07393048 — Application and Exploration of Personalized ctDNA-MRD Detection Technology in Predicting the Efficacy of Neoadjuvant The · recruiting
NCT07441850 — Digital Rehabilitation for Gastric Cancer Surgery After Neoadjuvant Therapy · NA · recruiting
NCT07369739 — Golidocitinib Combined With Selinexor for CAEBVD · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03764826 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Beijing Friendship Hospital
Last refreshed: 11 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03764826.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing